Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
From Editor to Dense Geometry Estimator
arXiv:2509.04338v2 Announce Type: replace-cross Abstract: Leveraging visual priors from pre-trained text-to-image (T2I) generative models has shown success in dense prediction. However, dense prediction is inherently an image-to-image task, suggesting that image editing models, rather than T2I generative models, may be a more suitable foundation for fine-tuning. Motivated by this, we conduct a systematic analysis of the fine-tuning behaviors of both editors and generators for dense geometry e
-
Nature Medicine
-
<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.
<i>LRRK2</i>-targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
Nature Medicine, Published online: 24 March 2026; doi:10.1038/s41591-026-04262-4
The first-in-human clinical trial of the LRRK2-targeting antisense oligonucleotide BIIB094 in Parkinson’s disease demonstrates that the treatment is well tolerated and produces dose-dependent reductions in cerebrospinal fluid levels of LRRK2 and phosphorylated Rab10, indicating successful target engagement.-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation
J Cancer. 2026 Jan 30;17(3):515-523. doi: 10.7150/jca.127381. eCollection 2026.ABSTRACTGastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide, largely due to their molecular heterogeneity, complex tumor microenvironment (TME), and variable treatment responses. In recent years, the emergence of spatially resolved omics technologies-encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics-has revolutionized the ability to int
Spatial Omics in Gastrointestinal Oncology: Recent Advances, Therapeutic Insights, and Clinical Translation
J Cancer. 2026 Jan 30;17(3):515-523. doi: 10.7150/jca.127381. eCollection 2026.
ABSTRACT
Gastrointestinal (GI) cancers remain a leading cause of cancer-related morbidity and mortality worldwide, largely due to their molecular heterogeneity, complex tumor microenvironment (TME), and variable treatment responses. In recent years, the emergence of spatially resolved omics technologies-encompassing spatial transcriptomics, proteomics, metabolomics, and epigenomics-has revolutionized the ability to interrogate tumor architecture with unprecedented resolution. These methods enable precise mapping of cellular and molecular interactions within intact tissue contexts, thereby uncovering spatially defined niches that influence tumor progression, immune evasion, and therapeutic resistance. In GI malignancies such as colorectal, gastric, and esophageal cancers, spatial omics have provided critical insights into cancer-stromal-immune crosstalk, identified predictive biomarkers for immunotherapy and targeted agents, and guided the development of novel therapeutic strategies. This review synthesizes the latest advances in spatial omics applied to GI oncology over the past five years, with an emphasis on their integration into early diagnosis, treatment stratification, and real-time monitoring of therapeutic efficacy. We also discuss current challenges, including standardization, data integration, and clinical validation, as well as future directions for incorporating spatial profiling into routine oncology practice. By bridging the gap between bench discoveries and bedside applications, spatial omics hold transformative potential for achieving truly personalized treatment in gastrointestinal cancers.
PMID:41869445 | PMC:PMC13003551 | DOI:10.7150/jca.127381